Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Erba Describes Proper Diagnostic Testing of CML

February 27th 2012

Dr. Harry Erba, from the University of Michigan Health System, Describes Proper Diagnostic Testing of CML

Dr. Dunleavy Discusses 3 Molecular Subtypes of DLBCL

February 24th 2012

Dr. Kieron Dunleavy from the National Cancer Institute Discusses 3 Molecular Subtypes of DLBCL

Current Trends in the Treatment of Newly Diagnosed Myeloma

February 24th 2012

A number of studies suggest that there is a right and wrong way to proceed with initial therapy and transplant eligibility for patients with multiple myeloma.

New Directions in Relapsed/Refractory Diffuse Large B-cell Lymphoma

February 24th 2012

Research has shown that DLBCL is heterogeneous, suggesting that patients with varying subtypes should receive different courses of treatment.

Dr. Ansell on Waldenstrom Macroglobulinemia Types

February 24th 2012

Dr. Stephen Ansell from the Mayo Clinic Describes WaldenstrÃ¶m Macroglobulinemia

Nilotinib Responses Better Than Imatinib in CML Trials

February 23rd 2012

Two phase III clinical trials showed that nilotinib continues to demonstrate more favorable molecular response levels in patients with Ph CML than imatinib mesylate.

Dr. Hamlin on Integrating Brentuximab Vedotin

February 10th 2012

Dr. Paul Hamlin, from Memorial Sloan-Kettering Cancer Center, Discusses Integrating Brentuximab Vedotin

Dr. Rosenbloom on Gaucher Disease Diagnosis Challenges

February 10th 2012

Dr. Barry Rosenbloom, from the Comprehensive Gaucher Treatment Center, on Gaucher Disease Diagnosis Challenges

Dr. Berenson on Zometa as the Gold Standard for Myeloma

February 9th 2012

Dr. James Berenson, from the Institute for Myeloma & Bone Cancer Research, on Zometa as the Gold Standard for MM

Novel Therapeutics Have Revolutionized Multiple Myeloma Treatment

February 2nd 2012

Novel therapeutics, including thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade), have revolutionized the treatment of multiple myeloma.

Treatment of Large Cell Lymphoma: R-CHOP and Beyond

January 31st 2012

The treatment of diffuse large B-cell lymphoma continues to evolve, as researchers seek to improve upon the current standard of care.

Taking Comfort

January 30th 2012

Much has been made of the difficulties companies, investigators, and patient advocates have in providing access to novel therapies.

Dr. Hamlin on Brentuximab Vedotin Pharmacology

January 26th 2012

Dr. Paul Hamlin from the Memorial Sloan-Kettering Cancer Center on Brentuximab Vedotin Pharmacology

Noted Researcher Sees ERT as Remarkable Beginning

January 26th 2012

The treatment of Gaucher disease is poised to enter a new era as a result of advances in the understanding of the cellular pathways at work in the disorder.

Dr. Weinreb on the Different Roles in a Gaucher Diagnosis

January 26th 2012

Dr. Neal Weinreb, from University Research Foundation for Lysosomal Storage Diseases, on the Different Roles in a Gaucher Diagnosis

Dr. Zimran Discusses Gaucher Disease Biomarkers

January 26th 2012

Dr. Ari Zimran, from Shaare Zedek Medical Center, Jerusalem, Discusses Biomarkers in Gaucher Disease

Nonmyeloablative Conditioning Before Cell Transplantation Shows Potential in Older Patients With Hematologic Malignancies

January 26th 2012

Older patients with advanced hematologic malignancies who receive a minimally toxic nonmyeloablative regimen before allogeneic HCT have favorable OS and PFS rates.

FDA Approves Genzyme's Fabrazyme Plant

January 24th 2012

Genzyme Corporation announced that the FDA has approved its new manufacturing plant in Framingham, Massachusetts.

Dr. Berenson Discusses Early Phase Proteasome Inhibitors

January 24th 2012

Dr. James Berenson, from the Institute for Myeloma and Bone Cancer Research, Discusses Early Phase Proteasome Inhibitors

Bortezomib Approved for Subcutaneous Injection

January 24th 2012

The FDA has deemed subcutaneous injection as a safe and valid method of delivering the drug bortezomib in patients with multiple myeloma.